The Health Secretary said his “central expectation” was that a vaccine rollout could be underway in the first half of 2021, with “the bulk” expected before next summer.
It follows a report by The Sun newspaper that London’s health chiefs are on standby to receive deliveries from the Jab Oxford-AstraZeneca from the “week starting November 2″.
Mr Hancock said: “On my central expectation, I would expect the bulk of the deployment to be in the first half of next year. ”
The latest coronavirus news from the UK and around the world
Asked about reports that hospitals are preparing to vaccinate staff, Mr Hancock added: ‘We want to be ready in case everything goes perfectly. ”
“But it’s not my main expectation that we’ll be doing this this year. ”
He also told the BBC’s Today program: “But, you know, preparing for a deployment and having the items to deploy are two different things.
“This is obviously something that we want to happen as soon as possible safely. And as fast as safe as possible, but we’re not there yet. ”
Although he refused to completely exclude some coronavirus jabs this year.
“Well, I’m not ruling that out, but that’s not my main expectation,” he said.
the COVID-19[feminine[feminine The vaccine developed by the University of Oxford and UK pharmaceutical company AstraZeneca is widely regarded as one of the pioneers in the global vaccine race.
Results from a trial showed the vaccine produced an immune response in the elderly and young, AstraZeneca said Monday. The vaccine also triggers weaker side reactions in the elderly.
:: Subscribe to the daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker
The results echo July’s results which show the vaccine produced “robust immune responses” in healthy adults between the ages of 18 and 55.
A spokesperson for AstraZeneca said the results were “encouraging” and “further strengthen the body of evidence of the vaccine’s safety and immunity capabilities.”
AstraZeneca has signed multiple supply and manufacturing agreements with companies and governments around the world as it nears the first results of an advanced clinical trial. The British government has signed an agreement for 100 million doses.
The vaccine is in phase 3 trials – the last step before a treatment is declared safe – in several countries, including the United States and India.